Evidence map›Paper›PMID 38307806›Full record

Trial reportEuropean urology focus2024

Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.

Kimberley S Mak, Molly Scannell Bryan, James J Dignam, William U Shipley, Yue Lin, Christopher A Peters, Elizabeth M Gore, Seth A Rosenthal, Kenneth L Zeitzer, David P D'Souza and 13 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European urology focus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Cardiovascular Risk in Prostate Cancer:JACC. CardioOncology · 2024
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 2 countries.

Kimberley S MakBoston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA. Electronic address: kimberley.mak@bmc.org.
Molly Scannell BryanUniversity of Illinois Cancer Center, Chicago, IL, USA.
James J DignamUniversity of Chicago, Chicago, IL, USA; NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA.
William U ShipleyMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yue LinBoston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Christopher A PetersNortheast Radiation Oncology Center, Dunmore, PA, USA.
Elizabeth M GoreMedical College of Wisconsin and the Zablocki Veteran Affairs Medical Center, Milwaukee, WI, USA.
Seth A RosenthalSutter Cancer Centers, Roseville, CA, USA.
Kenneth L ZeitzerAlbert Einstein Medical Center, Philadelphia, PA, USA.
David P D'SouzaLondon Regional Cancer Program, London, ON, Canada.
Eric M HorwitzFox Chase Cancer Center, Philadelphia, PA, USA.
Thomas M PisanskyMayo Clinic, Rochester, MN, USA.
Jordan M MaierWayne State University-Karmanos Cancer Institute, Detroit, MI, USA.
Susan M ChafeCross Cancer Institute, Edmonton, AB, USA.
Tyler P RobinUniversity of Colorado Hospital, Aurora, CO, USA.
Mack RoachUniversity of California San Francisco, San Francisco, CA, USA.
Phuoc T TranUniversity of Maryland, Baltimore, MD, USA.
Luis SouhamiThe Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jeff M MichalskiWashington University School of Medicine, Saint Louis, MO, USA.
Alan C HartfordDartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, NH, USA.
Felix Y FengUniversity of California San Francisco, San Francisco, CA, USA.
Howard M SandlerCedars-Sinai Medical Center, Los Angeles, CA, USA.
Jason A EfstathiouMassachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Boston University · USHarvard University · USUniversity of California, San Francisco · USUniversity of Illinois Chicago · USCancer Care Ontario · CACedars-Sinai Medical Center · USCotton (United States) · USEinstein Medical Center Philadelphia · USFox Chase Cancer Center · USMayo Clinic in Arizona · USMcGill University Health Centre · CAMilwaukee VA Medical Center · USNortheast Radiation Oncology Center · USSutter Roseville Medical Center · USUniversity of Colorado Hospital · USUniversity of Maryland, Baltimore · USWashington University in St. Louis · USWayne State University · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

backgroundAndrogen deprivation therapy (ADT) has been associated with coronary heart disease and myocardial infarction (MI) in prostate cancer patients, but controversy persists regarding its effects on cardiovascular mortality (CVM).

objectiveWe assessed the long-term relationship between ADT and CVM in a prostate cancer randomized trial (NRG Oncology/Radiation Therapy Oncology Group 9202). DESIGN, SETTING, AND

participantsFrom 1992 to 1995, 1554 men with locally advanced prostate cancer (T2c-T4, prostate-specific antigen <150 ng/ml) received radiotherapy with 4 mo (short-term [STADT]) versus 28 mo (longer-term [LTADT]) of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using the Fine-Gray and Cox regression models, the relationship between ADT and mortality was evaluated. RESULTS AND LIMITATIONS: With a median follow-up of 19.6 yr, LTADT was associated with improved overall survival (OS) versus STADT (adjusted hazard ratio [HR] 0.88; p = 0.03) and prostate cancer survival (subdistribution HR [sHR] 0.70, p = 0.003). Comparing LTADT with STADT, prostate cancer mortality improved by 6.0% (15.6% [95% confidence interval 13.0-18.3%] vs 21.6% [18.6-24.7%]) at 15 yr, while CVM increased by 2.2% (14.9% [12.4-17.6%] vs 12.7% [10.4-15.3%]). In multivariable analyses, LTADT was not associated with increased CVM versus STADT (sHR 1.22 [0.93-1.59]; p = 0.15). An association between LTADT and MI death was detected (sHR 1.58 [1.00-2.50]; p = 0.05), particularly in patients with prevalent cardiovascular disease (CVD; sHR 2.54 [1.16-5.58]; p = 0.02).

conclusionsWith 19.6 yr of follow-up, LTADT was not significantly associated with increased CVM in men with locally advanced prostate cancer. Patients may have increased MI mortality with LTADT, particularly those with baseline CVD. Overall, there remained a prostate cancer mortality benefit and no OS detriment with LTADT. PATIENT SUMMARY: In a long-term analysis of a large randomized prostate cancer trial, radiation with 28 mo of hormone therapy did not increase the risk of cardiovascular death significantly versus 4 mo of hormone therapy. Future studies are needed for patients with pre-existing heart disease, who may have an increased risk of myocardial infarction death with longer hormone use.

Indexed as

Androgen AntagonistsCardiovascular DiseasesProstatic NeoplasmsAgedFollow-Up StudiesHumansMaleMiddle AgedProportional Hazards ModelsTime FactorsAndrogen AntagonistsAndrogen deprivation therapyCardiovascular mortalityHormonal therapyProstate cancerRadiation therapy

Identifiers

PMID38307806
PMCPMC11257781
OpenAlexW4391482149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.